Francesco Pinto
Angelo Totaro
Alessandro Calarco
Emilio Sacco
Andrea Volpe
Marco Racioppi
Alessandro D'Addessi
Gaetano Gulino
PierFrancesco Bassi

Department of Urology, Catholic
 University of Sacred Heart, Rome, Italy

Imaging in Prostate Cancer Diagnosis: Present Role and Future Perspectives

Key Words

Prostate cancer • Magnetic resonance imaging •
 Diffusion-weighted MRI • Dynamic contrast-enhanced MRI •
 MR spectroscopy • Prostate ultrasonography imaging •
 Prostate biopsy

Abstract

Prostate cancer (PCa) remains a major health concern for the male population. Detection and primary diagnosis of PCa are based on digital rectal examination, serum prostate-specific antigen levels, and transrectal ultrasound (TRUS)-guided random biopsy. Moreover, the gold standard for detecting PCa, systematic biopsy, lacks sensitivity as well as grading accuracy. This review summarizes recent developments of ultrasonography modalities and functional magnetic resonance imaging (MRI) in the diagnosis of PCa. A comparison between the different methods is presented, including their clinical value and usefulness. It is concluded that innovative ultrasound techniques (including ultrasound contrast agents, 3-D and 4-D sonography, elastography and harmonic sonography) promise benefits in comparison to standard TRUS to accurately diagnose PCa. Promising advances have been made in the detection of PCa with multiparametric MRI. The combination of conventional and functional MRI techniques (including diffusion-weighted imaging, dynamic contrast-enhanced MRI, and MR spectroscopy) can provide information for differentiating PCa from noncancerous tis-

sue and can be used for MRI-guided biopsies, especially in patients with persistent elevation of serum prostate-specific antigen and previous negative TRUS-guided biopsies. However, functional MRI technique and MRI-guided biopsy remain expensive and complex tools presenting inherent challenges.

Copyright © 2011 S. Karger AG, Basel

Introduction

Prostate cancer (PCa) is the most common cancer in men in Europe [1]. Among men in the EU, PCa accounts for approximately 11.9% of all cancers and 9% of all cancer deaths [1]. Despite advances in PCa detection and treatment, the disease continues to represent an enormous healthcare burden. Early PCa detection is the main topic of diagnostic imaging and the key to successful cancer treatment [2]. To date, the suspicion of PCa is mainly based on three diagnostic tools: serum prostate-specific antigen (PSA), digital rectal examination (DRE) and transrectal ultrasound (TRUS) of the prostate, each of them presenting well-known limitations [2, 3]. Nowadays, random TRUS-guided biopsy is the gold standard method for histological diagnosis of PCa [4]. However, random biopsies have several disadvantages: (a) missing cancer in up to 35% of cases [4]; (b) presence of multiple foci in more than 85% of cases of PCa [5]; (c) increase in

complications because of unnecessary biopsies. Moreover, men with persistently elevated PSA levels after a negative first random TRUS-guided biopsy represent a great diagnostic challenge for urologists [6]. For these reasons, new imaging techniques are necessary to allow PCa visualization in order to improve cancer detection rate. To date, no consensus exists regarding the use of imaging techniques for evaluating primary PCas. Current standard imaging techniques, such as ultrasound, magnetic resonance imaging (MRI), CT, and nuclear medicine, cannot detect early disease, and they provide limited information for disease staging [7]. However, several promising emerging techniques are under investigation, either alone or in conjunction with standard imaging techniques. Evolving methods such as 3-D/4-D TRUS, contrast-enhanced ultrasound techniques, elastography and multiparametric MRI such as dynamic contrast material-enhanced MRI (DCE-MRI), diffusion-weighted imaging (DWI), and MR spectroscopy imaging may dramatically change the role of imaging for PCa diagnosis [8–13]. The aim of this article is to review the current clinical status of advanced imaging techniques and future perspectives for the detection of PCa.

Evidence Acquisition

The authors searched the Medline, Embase, and Cochrane Library databases. Only studies in English were evaluated. The last search was performed in June 2010.

Sonography Imaging

Transrectal Ultrasonography

TRUS provides real-time imaging of the prostate gland at a relatively low cost. However, it suffers from lack of specificity, especially if the investigator is still fairly inexperienced [14]. To improve PCa detection, various biopsy strategies have been devised to increase the diagnostic yield of prostate biopsy: sampling of visually abnormal areas, more lateral placement of biopsies, anterior biopsies, and obtaining an increased number of cores, with up to 45 biopsy cores [15–18]. On the one hand, the efficiency of this practice is debated and limited in practice by patient tolerance and morbidity. On the other hand, several studies have shown that systematic biopsy still misses a considerable number of PCa [19, 20]. On gray-scale evaluation, PCa are classically described as a hypoechoic lesion; however, they may be isoechoic or hyperechoic [14]. Many PCa are not visible on standard ultrasound, and the predictive value of hypoechoic lesion is 25–30%

[17]. Therefore, new strategies for PCa detection have been investigated to improve the quality of the investigation instead of raising the quantity of biopsies, and thus to reduce the number of unnecessary ‘blind’ biopsies.

Innovative Sonography Techniques

3-D/4-D Sonography. It is essential when performing prostate ultrasound to carefully evaluate the entire gland for different types of lesions and to perform biopsies on subtle as well as obvious lesions, in addition to performing random biopsies to identify ‘invisible’ cancers. Gray-scale 2-D TRUS has relatively poor ability to detect palpable and nonpalpable cancers and predict disease outcome [20]. 3-D ultrasound has become mainstream in gynecologic and obstetric application, but the use in urologic application is relatively limited. 3-D ultrasound allows simultaneous biplanar imaging of the prostate with computer reconstructions providing a coronal plane as well as a rendered 3-D image. 3-D ultrasound of prostate improves the diagnostic accuracy for exact localization of only hypoechoic areas, particularly on the coronal view [21]. Moreover, a recent study of Abul et al. [22] showed an improvement in diagnostic accuracy of PCa for 4-D TRUS. Nevertheless, there is still a group of patients with ‘invisible’ cancers. Therefore, the policy of random biopsies has to be continued until this incidence can be eliminated.

Contrast-Enhanced Sonography. Using intravenous microbubble agents in combination with color and power Doppler imaging modalities, an increase in signal is obtained in areas of increased vascularity. In a study conducted by Pelzer et al. [23] on 380 patients with suspected PCa (PSA level between 4 and 10 ng/ml), contrast-enhanced color Doppler-targeted biopsies (five cores) in areas of hypervascularity were compared with standard biopsies (10 cores). Based on cancer detected by biopsy, the detection rate of targeted biopsy cores was significantly better than standard biopsy cores (32.6 vs. 17.9%, $p < 0.01$) [23]. Similar results were found in another study conducted by Halpern [24] on 301 patients, in which targeted biopsy was 1.5 times more likely to find tumor than was systematic biopsy (15.5 vs. 10.4%, $p < 0.01$). Nevertheless, targeted biopsies missed 20% of cancers, which were detected on systematic biopsy alone, leading to the conclusion that systematic biopsy could not be omitted from a biopsy scheme [24]. The study by Yi et al. [25] demonstrated that the sensitivity on biopsy site was greater on contrast-enhanced sonography (68%) than on gray-scale (39%) and color Doppler (41%) sonography. Moreover, Drudi et al. [26] demonstrated that contrast-enhanced sonography may also be used in the diagnosis

of local recurrence after radical prostatectomy in patients with increasing PSA.

Harmonic Sonography. Intermittent imaging is an ultrasound technique that employs a reduced frame rate, allows more time for the contrast agent to enter the scan plane between frames, and thereby increases the intensity of microbubble contrast enhancement [27, 28]. Preliminary data suggest that intermittent gray-scale harmonic imaging (IHI) can increase the conspicuity of microvascular enhancement associated with PCa [29]. Moreover, in the study conducted by Halpern [24], it has been demonstrated that contrast-enhanced transrectal sonography with IHI provides a statistically significant improvement in discrimination between benign and malignant biopsy site, and the carcinoma detection rate of contrast-enhanced targeted cores is significantly higher when compared with sextant cores. However, given the relatively low ROC areas (<0.65), this technique did not definitively differentiate benign from malignant tissue without biopsy confirmation.

Elastography. Elastography is an imaging technique that evaluates the elasticity of the tissue. Prostate carcinomas are characterized by a partly limited elasticity or compressibility. Miyanaga et al. [30] investigated 29 patients with untreated PCa. The sensitivity of elastography, TRUS and DRE was 93, 59 and 55%, respectively [30]. Thus, elastography may be used as biopsy guidance in the diagnosis of PCa. In a pilot study on 404 patients, König et al. [31] have demonstrated an improved PCa detection rate (20%) when combining this method with conventional TRUS during prostate biopsies. In a recent study on 492 patients, Pallwein et al. [32] showed that elastography-targeted biopsy in a patient with cancer was 2.9-fold more likely to detect PCa than systematic biopsy, with fewer than half the number of biopsy core. Although the results with elastography had shown some promising results, its role in PCa diagnosis needs to be evaluated further.

Pre-Biopsy MRI and Real-Time TRUS: Near Future

In a recent study, Singh et al. [33] described the feasibility of fusing pre-biopsy MRI data with real-time TRUS imaging using fiducial markers. In another study, Xu et al. [34] proposed a hybrid registration approach for real-time MRI/TRUS image fusion, bringing the diagnostic information from the MRI to ultrasound procedures. The approach is based on both spatial tracking and intraoperative image registration, which allows compensation for prostate motion without the use of fiducial markers. That way, it is likely that in the near future, can-

Fig. 1. Normal prostate gland, endorectal MRI, axial image. **a** T₁-WI: prostate shows a uniform intermediate signal intensity. **b** T₂-WI: prostate shows a high signal intensity of the peripheral and low signal intensity of the central and transitional zones. PZ = Peripheral zone; TZ = transitional zone.

cers could be identified at MRI, contoured, transferred to the ultrasound device and superimposed on real-time ultrasound imaging to improve their aiming of targeted biopsies and facilitate potential MRI-guided prostate therapies such as external beam radiation therapy, brachytherapy, cryotherapy, HIFU ablation, or direct injection of agents [35]. In this way, multi-modality imaging with electromagnetic tracking of enabled devices can draw from the benefits of one method, while avoiding the limitations of another. For example, this perspective is especially interesting for anterior cancers that can be detected at pre-biopsy MRI but lie in a 'gray zone' of the TRUS biopsies (18–20 mm beyond the capsule) and additionally cannot be targeted using standard ultrasound imaging.

Magnetic Resonance Imaging

Conventional MRI at 1.5 or 3.0 T reveals morphological information using T₁- and T₂-weighted images (T₁- and T₂-WI), and the usage of an endorectal coil can improve the detection of PCa and the delineation of the capsule [36] (fig. 1, 2). The value of 3.0-tesla MRI of the prostate is recently under research and seems to be promising [36, 37]. T₂-WI provides high-resolution morphologic imaging of the gland in the three planes, and axial T₁-WI is used to detect post-biopsy hemorrhage, lymph nodes, and bone metastasis. On T₂-WI, peripheral zone cancer typically shows a uniformly low signal with a nod-

Fig. 2. Normal prostate gland, endorectal MRI, coronal image.

ular shape within the peripheral zone that shows high signal intensity [38] (fig. 3). However, there are numerous false positives because low intense signal in peripheral zone can also be caused by inflammation, hemorrhage, sequelae of radiation and hormonal treatment, etc. For this reason, MRI should be delayed for at least 4–8 weeks after prostate biopsy [39, 40]. In the transitional zone, cancer detection on T_2 -WI is hampered by benign hyperplastic nodules that have highly variable signal (from high-intensity cysts to very-low-intensity stromal nodules) and a nodular appearance. Thus, the sensitivity and specificity of T_2 -weighted MR imaging for PCa detection have varied widely. Sensitivity of 77–91% and specificity of 27–61% were reported for PCa detection with T_2 -weighted imaging performed with an endorectal coil [41, 42]. In the last two decades, intense research has focused on complementary techniques to improve the detection and staging of PCa. In a recent review on multiparametric MRI in PCa, Kurhanewicz et al. [43] concluded that the best characterization of PCa in individual patients will most likely result from multiparametric MRI techniques based on anatomic, metabolic and physiologic properties of PCa, using 3-tesla magnetic resonance scanners. However, questions remain as how to analyze and display this large amount of imaging data, and how to optimally combine the data for the most accurate assessment of PCa. Cancer identification at MRI requires a combination of morphologic T_2 -WI and functional imaging (perfusion, diffusion, and spectroscopy). Currently used functional MRI techniques include: magnetic resonance spectroscopic imaging (MRSI), dynamic contrast-enhanced MRI, and DWI-MRI. A magnet strength of at

Fig. 3. T_2 -weighted axial (a) and coronal (b) images with endorectal coil show an area of low signal intensity (arrow) in the right peripheral zone of the prostate, a finding indicative of a tumor.

least 1.5 T is required for a simultaneous use of MRI and MRSI in order to overlay metabolic information directly on the corresponding anatomic display [44, 45].

Magnetic Resonance Spectroscopic Imaging

MRSI allows assessment of tissue metabolism in a single or multiple voxels. The metabolites measured by in vivo MRSI are citrate, creatine, choline and polyamines [46]. Typically, PCa shows a high level of choline and a low level of citrate relative to the normal peripheral zone with a high specificity but at the expense of sensitivity [46–48] (fig. 4).

In the last decade, many publications have studied the advantages of the combined use of MRI and MRSI in order to combine metabolic information directly on the corresponding anatomic display [44, 45]. A study conducted by Scheidler et al. [49] showed a sensitivity and specificity for PCa detection, on a per-sextant basis, of 95 and 91%, respectively, for combined MRSI and MRI, but 61–77 and 46–81% for MRI alone and 75 and 63% for MRSI alone. This study demonstrated that the addition of MRSI to MRI significantly improves PCa localization: for locations in the peripheral zone, PPV and NPV were 89–92 and 74–82%, respectively. Moreover, combined MRI-MRSI seems to be superior to sextant biopsy, with the largest increase in diagnostic accuracy at the apex of the prostate, which is difficult to reach by biopsy [50]. In two recent prospective studies conducted on 39 and 42 patients with elevated PSA levels, that used prostate biopsy as reference standard, it has been reported that combined MRI and MRSI increase the accuracy in PCa detection and localization to 79 and 74.2%, respectively [51,

Fig. 4. MRI and MRSI from a patient with PCa. **a** T₂-weighted axial image shows a large region of hypointensity in the right mid-gland (arrow). **b** Spectrum obtained from the same area demonstrates an elevated ratio of choline (Cho) and creatine (Cr) to citrate (Ci).

52]. However, Prando et al. [53] found that prostate biopsy directed with endorectal MRSI may help to increase the PCa detection rate in patients with an elevated PSA and a previous negative biopsy result.

Limitations of MRSI are: long acquisition time, possible variability in results dependent on post-processing or shimming, no direct visualization of the periprostatic anatomy and therefore expensive procedure. In addition, a previous prostate biopsy may lead to spectral degradation which makes accurate interpretation of the metabolite ratios unreliable, although an MRSI should not be performed within 8 weeks after biopsy [54]. These limitations of MRSI might be improved by new technical developments and the use of higher magnetic fields (3.0 T). Further studies would be desirable to compare US techniques (i.e. high resolution, contrast enhanced, and elastography) with combined MRI/MRSI findings for PCa detection. Moreover, the high specificity of MRSI is of interest to assess low-risk patients who may be candidates for watchful waiting or deferred therapy [55].

Dynamic Contrast Material-Enhanced MRI

It is well known that the number of vessels increases in cancerous tissue and tumor vessels have a greater permeability [56]. Experimental studies have shown that contrast enhancement parameters, such as mean transit time, blood flow, permeability surface area and interstitial volume, are significantly higher in cancerous tissue than in normal tissue, and therefore allow differentiation between benign and malignant tissue [57–61]. DCE-MRI

Fig. 5. **a** DCE-MRI image shows a lesion with early enhancement in the right peripheral zone. **b** Perfusion graph shows an early enhancement peak, followed by washout in the tumor area and progressive and persistent enhancement of the normal peripheral zone on the left.

is based on repetitive acquisition of sequential images during the passage of a contrast agent within a tissue of interest (fig. 5). Clinical experiences with this technique were first reported in the mid-1990s and, at present, there are only limited data on T₂-WI MRI and PCa in the literature. Engelbrecht et al. [62] and Kim et al. [63] showed the usefulness of measurements of relative peak enhancement, and wash-in and wash-out rate for PCa detection and localization. In their study, sensitivity and specificity of peripheral zone cancer detection on parametric images of the wash-in rate were 96 and 97%, respectively, but 75 and 53% on T₂-WI ($p < 0.05$). However, they also observed significant overlap between the wash-in rate for cancer and that for normal tissue in the transitional zone. Several studies on DCE-MRI that used surgical pathology as the reference standard have reported sensitivity, specificity, and accuracy levels ranging from 69 to 95%, from 80 to 96.2%, and from 77.5 to 92%, respectively [63–67]. In a prospective study of 34 patients, with a mean PSA of 8 ng/ml, using whole-mount histopathology section findings as the reference standard, Fütterer et al. [68] found that for the localization of tumors with volumes of ≥ 0.5 cm³, interpretation of T₁-WI of DCE-MRI in conjunction with T₂-WI of MRI led to an increase in sensitivity from 69 to 95%, specificity from 80 to 96% and accuracy from 81 to 93%. Moreover, combined DCE-MRI and 3-D MRSI significantly improve the accuracy in PCa localization, compared with T₂-WI MRI alone ($p < 0.01$) [67]. However, more recently, Jackson et al. [69] reported that DCE-MRI sensitivity was higher than conventional

Fig. 6. **a** T₂-weighted axial image shows an area of hypointense signal in the left peripheral zone (arrow). **b** The corresponding DWI-MRI shows restricted diffusion in the same area, most consistent with PCa. Histopathology showed a tumor with a Gleason score of 7.

MRI (T₂-WI) for tumor localization (50 vs. 21%; $p = 0.006$), but specificity was similar (85 vs. 81%; $p = 0.593$). The superior sensitivity of DCE-MRI compared with T₂-WI, together with its high specificity, is arguably sufficient for its use in guiding radiotherapy boosts in PCa.

Thus, DCE-MRI has the advantage of providing direct depiction of tumor vascularity and may obviate the use of an endorectal coil. Nevertheless, the limitations of this technique include unsatisfactory depiction of transitional zone cancer in patients with hypervascular benign prostatic hyperplasia. In addition, there is as yet no consensus with regard to the best acquisition protocol and the optimal perfusion parameter for differentiating cancer from normal tissue.

Diffusion-Weighted MRI

The diffusion properties of tissue are related to the amount of interstitial free water and permeability [70]. DW-MRI derives its image contrast from differences in the motion of water molecules between tissues. In general, cancer tends to have more restricted diffusion than normal tissue, because of the higher cell densities and abundance of intra- and intercellular membranes in cancer [70, 71]. These images can be acquired quickly without the administration of exogenous contrast medium. DW-MRI yields qualitative and quantitative information: qualitative assessment of relative tissue signal attenuation at DW-MRI is used for tumor detection and characterization; quantitative analysis of DW-MRI is achieved by calculation of the apparent diffusion coefficient

(ADC). The ADC is calculated for each pixel of the image and is displayed as a parametric map (ADC map) [72] (fig. 6). A retrospective study comparing MRI alone to combined DW-MRI/MRI in 124 patients with clinically suspected PCa demonstrated that the addition of DW imaging to conventional T₂-WI imaging significantly improved tumor detection ($p = 0.0468$) compared with conventional MRI alone [73]. The sensitivity, specificity, PPV, and NPV of combined DW-MRI/MRI for PCa detection were reported to be 86, 84, 90, and 79%, respectively [73]. A recent study [74] showed that ADC values of malignant prostate tissue were significantly lower than in benign tissue. In this study, DW-MRI had a reported sensitivity of 86.7% and specificity of 72.2% for PCa detection in the peripheral zone [74], and the water diffusion within prostate tumors was significantly different in patients with low-risk disease than in patients with intermediate or high-risk disease. The authors concluded that DW-MRI can potentially identify poorly differentiated tumors, as these demonstrate earlier and faster enhancement [74]. However, other studies did not confirm these findings [75–78]. DWI has advantages such as short acquisition time and high contrast resolution between tumors and normal tissue. Nevertheless, this technique is limited by poor spatial resolution and the potential risk of image distortion caused by post-biopsy hemorrhage, which results in magnetic field inhomogeneity [70–74].

Role of MRI after Previous Negative Biopsy

One of the most challenging aspects of PCa diagnosis concerns patients with persistent elevation of serum PSA levels and previous negative TRUS-guided random biopsies of the prostate. It has been recommended that these patients repeat biopsy [79, 80]. The concept of performing MRI prior to biopsies has been evaluated, and several recent studies focus on this clinical setting [81, 82]. In one study published by Perrotti et al. [83] in 1999, the ability of endorectal MRI to detect PCa foci was examined prospectively in 33 consecutive men with one or more prior negative prostatic biopsies. The areas of interest on endorectal MRI were mapped as low, moderate or high suspicion for carcinoma on a prostate model; directed needle biopsy cores of the prostate were obtained based on this model, and the histopathological findings were compared with MRI results: PPV, NPV and accuracy of endorectal MRI were 40% (moderate or high suspicion), 94.4% (low suspicion) and 69.7%, respectively [83]. On multivariate analysis, positive endorectal MRI was associated with an 11.3-fold risk of positive biopsy [74]. In a prospective study conducted on 44 patients with a PSA

>4 ng/ml or suspicious free-to-total PSA ratios (i.e. <15%) in whom prior TRUS-guided biopsy failed to demonstrate a tumor, Beyersdorff et al. [9] found that MRI had a sensitivity of 83% and a PPV of 50% for PCa detection. These values were 33 and 67% for DRE, and 33 and 57% for TRUS, respectively [9]. Moreover, in retrospective site-by-site analysis, MRI results did not correlate significantly with individual biopsy site findings ($p = 0.126$); sensitivity was 65% and PPV was 12% [9]. In another study, Comet-Batlle et al. [10] assessed the value of endorectal MRI in the early diagnosis of PCa, and compared this test to PSA and DRE in the prediction of negative biopsies. They concluded that, in patients with elevated PSA and/or abnormal DRE with two previous negative biopsies, MRI is a useful test to rule out PCa when negative, avoiding subsequent biopsies, as they have a low chance of positive biopsy. More recent studies have been conducted to assess the value and the ability of combined conventional/functional MRI to detect PCa foci in men with prior negative TRUS-guided prostate biopsy [11, 84–87]. The study by Yuen et al. [11] investigated 24 patients with prior negative TRUS-guided prostate biopsy. Sensitivity, specificity, PPV, NPV, and the accuracy of MRI, MRSI and combined MRI/MRSI for PCa detection were 57.1, 57.1 and 100.0% (sensitivity), 88.2, 82.4 and 70.6% (specificity), 66.7, 57.1 and 58.3% (PPV), 83.3, 82.1 and 100% (NPV), and 79.2, 75.0 and 79.2% (accuracy), respectively [11]. Similar results were found by Bhatia et al. [84], in which sensitivity, specificity, PPV, NPV and accuracy of combined MRI/MRSI for detection of PCa were 100, 84, 40, 100, and 86%, respectively. More recently, Sciarra et al. [85] prospectively analyzed the role of magnetic MRSI and DCE-MR in the detection of prostate tumor foci in 180 patients with persistently elevated prostate-specific antigen levels (in the range of ≥ 4 ng/ml to <10 ng/ml) and prior negative random biopsy. This study demonstrated that MRSI had 92.3% sensitivity, 88.2% specificity, 85.7% PPV, 93.7% NPV, and 90% accuracy; DCE-MRI had 84.6% sensitivity, 82.3% specificity, 78.5% PPV, 87.5% NPV, and 83.3% accuracy; the association MRSI plus DCE-MRI had 92.6% sensitivity, 88.8% specificity, 88.7% PPV, 92.7% NPV, and 90.7% accuracy, for predicting PCa detection. In a recent review conducted by Lawrentschuk and Fleshner [86], six studies with a total of 215 patients were examined to assess the efficacy of MRI for targeting cancer when compared to biopsies in patients with previous negative prostate biopsies and persistently elevated PSA levels. The cancer detection rate at re-biopsy was 21–40%. For MRI or combined MRI/MR spectroscopy, the overall sensitivity, specificity and accu-

racy for predicting positive biopsies were 57–100, 44–96 and 67–85%, respectively [85]. In five studies, specific MRI-targeted biopsies and standard cores were taken, with a significant proportion (34/63, 54%) having cancer detected purely because of the MRI-targeted cores [85]. A recent study [87] suggested that combined DW-MRI/MRI on 3 T has the potential to provide important lesion localization before a repeat biopsy in patients with previous negative random biopsy and persistently elevated PSA levels.

Conclusions

The degree to which imaging techniques are seen as an indispensable and vital part in diagnostic procedures presents a specific quality feature in urology. To date, considerable advances have been made in organ-confined PCa imaging, particularly in functional MR. The addition of functional MR techniques to T_2 -weighted MRI can provide metabolic information, display altered cellularity and aid in noninvasive characterization of tissue and tumor vascularity. This may improve cancer detection, especially in patients with previous negative biopsies. Moreover, functional MRI has still several limitations, mainly the limited availability, the high costs and the lack of standardized imaging parameters. Another important limitation is the wide variability in the specificity and sensitivity values reported in several studies that causes anxiety among patients and unease for the urologist. Furthermore, studies comparing MRI-guided with real-time TRUS-guided biopsy have been performed, and newer ultrasound techniques such as contrast-enhanced US and elastography are available. Prostate MRI is still evolving, and the potential of the technology may improve its utility and efficacy; however, large studies are necessary to verify these preliminary results. One of the difficulties with a rapidly developing technology such as MRI is that as results are published, newer generations of equipment emerge, making the last data appear obsolete. This brings up two unanswered questions: how do we analyze and display this large amount of imaging data, and which kind of lesions are we willing to discover? However, it is important to focus on specific scenarios and critically review publications periodically so that we may pause, reflect on results and then redirect research questions as necessary. The risk of not doing so is that we may never completely define a technology or understand its relevance to current patients, or adequately plan to answer the remaining questions.

References

- 1 Farley J, Parkin DM, Steliarova-Foucher: Estimates of cancer incidence and mortality in Europe in 2008. *Eur J Cancer* 2010;46:765–781.
- 2 Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA: American Cancer Society Prostate Cancer Advisory Committee. *CA Cancer J Clin* 2010;60:70–98.
- 3 Aigner F, Pallwein L, Pelzer A, Schaefer G, Bartsch G, Nedden D, Frauscher F: Value of magnetic imaging in prostate cancer diagnosis. *World J Urol* 2007;25:351–359.
- 4 Norberg M, Egevad L, Holmberg L, Sparén P, Norlén BJ, Busch C: The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. *Urology* 1997;50:562–566.
- 5 Chen ME, Troncso P, Johnston DA, Tang K, Babaian RJ: Optimization of prostate biopsy strategy using computer based analysis. *J Urol* 1997;158:2168–2175.
- 6 Keetch DW, Catalona WJ, Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. *J Urol* 1994;151:1571–1574.
- 7 Kelloff GJ, Choyke P, Coffey DS, Prostate Cancer Imaging Working Group: Challenges in clinical prostate cancer: role of imaging. *AJR* 2009;192:1455–1470.
- 8 Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ, Stief C, Hricak H, Graser A: Functional magnetic resonance imaging in prostate cancer. *Eur Urol* 2009;55:801–814.
- 9 Beyersdorff D, Taupitz M, Winkelmann B, Fischer T, Lenk S, Loening SA, Hamm B: Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. *Radiology* 2002;224:701–706.
- 10 Comet-Battle J, Vilanova-Busquets JC, Saladié-Roig JM, Gelabert-Mas A, Barceló-Vidal C: The value of endorectal MRI in the early diagnosis of prostate cancer. *Eur Urol* 2003;44:201–208.
- 11 Yuen JS, Thng CH, Tan PH, Khin LW, Phee SJ, Xiao D, Lau WK, Ng WS, Cheng CW: Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. *J Urol* 2004;171:1482–1486.
- 12 Amsellem-Ouazana D, Younes P, Conquy S, Peyromaure M, Flam T, Debré B, Zerbib M: Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. *Eur Urol* 2005;47:582–586.
- 13 Lattouf JB, Grubb RL 3rd, Lee SJ, Bjurlin MA, Albert P, Singh AK, Ocak I, Choyke P, Coleman JA: Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. *BJU Int* 2007;99:1041–1046.
- 14 Flanigan RC, Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL: Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer: results of a multicenter clinical trial of 6,630 men. *J Urol* 1994;152:1506–1509.
- 15 Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J: Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. *J Urol* 2006;175:1605–1612.
- 16 Delongchamps NB, de la Roza G, Jones R, Jumbelic M, Haas GP: Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. *BJU Int* 2009;10:49–54.
- 17 Rifkin MD, Dähnert W, Kurtz AB: State of the art: endorectal sonography of prostate gland. *AJR Am J Roentgenol* 1990;154:691–700.
- 18 Chrouser KL, Lieber MM: Extended and saturation needle biopsy. *Curr Urol Rep* 2004;5:226–230.
- 19 Norberg M, Egevad L, Holmberg L, Sparén P, Norlén BJ, Busch C: The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. *Urology* 1997;50:562–566.
- 20 Loch T: Computerized supported transrectal ultrasound (CTRUS) in the diagnosis of prostate cancer. *Urologe A* 2004;43:1377–1384.
- 21 Balaji KC, Fair WR, Feleppa EJ, Porter CR, Tsai H, Liu T, Kalisz A, Urban S, Gillespie J: Role of advanced 2 and 3 dimensional ultrasound for detecting prostate cancer. *J Urol* 2002;168:2422–2425.
- 22 Abul FT, Arun N, Abu-Assi MA, Asbeutah AM: Transrectal ultrasound guided biopsy for detecting prostate cancer: can random biopsies be reduced using the 4-dimensional technique? *Int Urol Nephrol* 2007;39:517–524.
- 23 Pelzer A, Bektic J, Berger AP, Pallwein L, Halpern EJ, Horninger W, Bartsch G, Frauscher F: Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced colour Doppler targeted and systematic biopsy. *J Urol* 2005;173:1926–1929.
- 24 Halpern EJ, Ramey JR, Strup SE, Frauscher F, McCue P, Gomella LG: Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. *Cancer* 2005;104:2373–2383.
- 25 Yi A, Kim JK, Park SH, Kim KW, Kim HS, Kim JH, Eun HW, Cho KS: Contrast-enhanced sonography for prostate cancer detection in patients with indeterminate clinical findings. *Am J Roentgenol* 2006;186:1431–1435.
- 26 Drudi FM, Giovagnorio F, Carbone A, Ricci P, Petta S, Cantisani V, Ferrari FS, Marchetti F, Passariello R: Transrectal colour Doppler contrast sonography in the diagnosis of local recurrence after radical prostatectomy: comparison with MRI. *Ultraschall Med* 2006;27:146–151.
- 27 Colon PJ 3rd, Richards DR, Moreno CA, Murgo JP, Cheirif J: Benefits of reducing the cardiac cycle-triggering frequency of ultrasound imaging to increase myocardial opacization with FS069 during fundamental and second harmonic imaging. *J Am Soc Echocardiogr* 1997;10:602–607.
- 28 Broillet A, Puginier J, Ventrone R, Schneider M: Assessment of myocardial perfusion by intermittent harmonic power Doppler using SonoVue, a new ultrasound contrast agent. *Invest Radiol* 1998;33:209.
- 29 Halpern EJ, Verkh L, Forsberg F, Gomella LG, Mattrey RE, Goldberg BB: Initial clinical experience with contrast-enhanced sonography of the prostate. *Am J Roentgenol* 2000;174:1575–1580.
- 30 Miyanaga N, Akaza H, Yamakawa M, Oikawa T, Sekido N, Hinotsu S, Kawai K, Shimazui T, Shiina T: Tissue elasticity imaging for diagnosis of prostate cancer: a preliminary report. *Int J Urol* 2006;13:1514–1518.
- 31 König K, Scheipers U, Pesavento A, Lorenz A, Ermer H, Sengen T: Initial experiences with real-time elastography guided biopsies of the prostate. *J Urol* 2005;174:115–117.
- 32 Pallwein L, Mitterberger M, Struve P, Horninger W, Aigner F, Bartsch G, Gradl J, Schurich M, Pedross F, Frauscher F: Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. *Eur Radiol* 2007;17:2278–2285.
- 33 Singh AK, Kruecker J, Xu S, Glossop N, Guion P, Ullman K, Choyke PL, Wood BJ: Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. *BJU Int* 2007;101:841–845.
- 34 Xu S, Kruecker J, Turkbey B, Glossop N, Singh AK, Choyke P, Pinto P, Wood BJ: Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. *Comput Aided Surg* 2008;13:255–264.
- 35 Puech P, Huglo D, Petyt G, Lemaitre L, Villers A: Imaging of organ-confined prostate cancer: functional ultrasound, MRI and PET/computed tomography. *Curr Opin Urol* 2009;19:168–176.

- 36 Fütterer JJ, Engelbrecht MR, Jager GJ, Hartman RP, King BF, Hulsbergen-Van de Kaa CA, Witjes JA, Barentsz JO: Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils: local staging accuracy of prostate cancer using endorectal coil MR imaging. *Eur Radiol* 2007; 17:1055–1065.
- 37 Beyersdorff D, Winkel A, Hamm B, Lenk S, Loening SA, Taupitz M: MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. *Radiology* 2005;234:576–581.
- 38 Schnall MD, Pollack HM: Magnetic resonance imaging of the prostate. *Urol Radiol* 1990;12:109–114.
- 39 Ikonen S, Kivisaari L, Vehmas T, Tervahartala P, Salo JO, Taari K, Rannikko S: Optimal timing of post-biopsy MR imaging of the prostate. *Acta Radiol* 2001;42:70–73.
- 40 White S, Hricak H, Forstner R, Kurhanewicz J, Vigneron DB, Zaloudek CJ, Weiss JM, Narayan P, Carroll PR: Prostate cancer: effect of postbiopsy haemorrhage on interpretation of MR images. *Radiology* 1995;195:385–390.
- 41 Hricak H, White S, Vigneron D, Kurhanewicz J, Kosco A, Levin D, Weiss J, Narayan P, Carroll PR: Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. *Radiology* 1994;193:703–709.
- 42 Young JC, Jeong K, Namkug K, Kyoung WK, Eugene K: Functiona MR imaging of prostate cancer. *Radiographics* 2007;27:63–77.
- 43 Kurhanewicz J, Vigneron D, Carroll P, Coakley F: Multiparametric magnetic resonance imaging in prostate cancer: present and future. *Curr Opin Urol* 2008;18:71–77.
- 44 Chen ME, Troncoso P, Johnston DA, Tang K, Babaian RJ: Functional MR imaging of prostate cancer. *Radiographics* 2007;27:63–75.
- 45 Claus FG, Hricak H, Hattery RR: Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. *Radiographics* 2004;24:S167–S180.
- 46 Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, Jones KD, Carroll PR, Kurhanewicz J: Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. *Radiology* 2004;233:701–708.
- 47 Shukla-Dave A, Hricak H, Moskowitz C, Ishill N, Akin O, Kuroiwa K, Spector J, Kumar M, Reuter VE, Koutcher JA, Zakian KL: Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. *Radiology* 2007; 245:499–506.
- 48 Nakashima J, Tanimoto A, Imai Y, Mukai M, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Marumo K, Murai M: Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. *Urology* 2004;64:101–105.
- 49 Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, Zaloudek CJ, Nelson SJ, Carroll PR, Kurhanewicz J: Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging – clinicopathologic study. *Radiology* 1999;213:473–480.
- 50 Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, Mueller-Lisse U, Carroll PR, Kurhanewicz J: Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. *J Urol* 2000;164:400–404.
- 51 Manenti G, Squillaci E, Carlini M, Mancino S, Di Roma M, Simonetti G: Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience. *Radiol Med (Torino)* 2006;111:22–32.
- 52 Reinsberg SA, Payne GS, Riches SF, Ashley S, Brewster JM, Morgan VA, deSouza NM: Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. *AJR Am J Roentgenol* 2007;188:91–98, 153–159.
- 53 Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E: Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. *Radiology* 2005;236:903–910.
- 54 Coakley FV, Kurhanewicz J, Lu Y, Jones KD, Swanson MG, Chang SD, Carroll PR, Hricak H: Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. *Radiology* 2002;223:91–97.
- 55 Shukla-Dave A, Hricak H, Kattan MW, Pucar D, Kuroiwa K, Chen HN, Spector J, Koutcher JA, Zakian KL, Scardino PT: The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. *BJU Int* 2007;99:786–793.
- 56 Choyke PL: Contrast agents for imaging tumour angiogenesis: is bigger better? *Radiology* 2005;235:1–2.
- 57 Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE: Prostate cancer: evaluation of vascular characteristics with dynamic contrast enhanced T1-weighted MR imaging – initial experience. *Radiology* 2004; 233:709–715.
- 58 Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ: Pharmacokinetic parameters in CNS Gd-DTPA enhanced MRI. *J Comput Assist Tomogr* 1991;15:621–628.
- 59 Hoffmann U, Brix G, Knopp MV, Hess T, Lorenz WJ: Pharmacokinetic mapping of the breast: a new method for dynamic MR-mammography. *Magn Reson Med* 1995;33: 506–514.
- 60 Hawighorst H, Knopp MV, Debus J, Hoffmann U, Grandy M, Griebel J, Zuna I, Essig M, Schoenberg SO, DeVries A, Brix G, van Kaick G: Pharmacokinetic MRI for assessment of malignant glioma response to stereotactic radiotherapy: initial results. *J Magn Reson Imaging* 1998;8:783–788.
- 61 Port RE, Knopp MV, Hoffmann U, Milker-Zabel S, Brix G: Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. *J Magn Reson Imaging* 1999;10:233–241.
- 62 Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van de Kaa CA, de la Rosette JJ, Blickman JG, Barentsz JO: Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. *Radiology* 2003;229: 248–254.
- 63 Kim JK, Hong SS, Choi YJ, Park SH, Ahn H, Kim CS, Cho KS: Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. *J Magn Reson Imaging* 2005;22:639–646.
- 64 Jager GJ, Ruijter ET, van de Kaa CA, de la Rosette JJ, Oosterhof GO, Thornbury JR, Ruijs SH, Barentsz JO: Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. *Radiology* 1997;203:645–652.
- 65 Ogura K, Maekawa S, Okubo K, Aoki Y, Okada T, Oda K, Watanabe Y, Tsukayama C, Arai Y: Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. *Urology* 2001;57:721–726.
- 66 Kiessling F, Lichy M, Grobholz R, Heilmann M, Farhan N, Michel MS, Trojan L, Ederle J, Abel U, Kauczor HU, Semmler W, Delorme S: Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. *Eur Radiol* 2004;14:1793–1801.
- 67 Schlemmer HP: Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. *Eur Urol* 2005;47:582–586.
- 68 Fütterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, Hulsbergen-Van de Kaa CA, Witjes JA, Krabbe PF, Heerschap A, Barentsz JO: Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. *Radiology* 2006;241:449–458.
- 69 Jackson ASN, Reinsberg SA, Sohaib SA, Charles-Edwards M: Dynamic contrast-enhanced MRI for prostate cancer localization. *Br J Rad* 2002;82:148–156.

- 70 Tien RD, Felsberg GJ, Friedman H, Brown M, MacFall J: MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. *AJR Am J Roentgenol* 1994;162:671–677.
- 71 Eis M, Els T, Hoehn-Berlage M: High resolution quantitative relaxation and diffusion MRI of three different experimental tumors in rat. *Magn Reson Med* 1995;34:835–844.
- 72 Koh DM, Collins DJ: Diffusion-weighted MRI in the body: applications and challenges in oncology. *AJR Am J Roentgenol* 2007;188:1622–1635.
- 73 Shimofusa R, Fujimoto H, Akamata H: Diffusion-weighted imaging of prostate cancer. *J Comput Assist Tomogr* 2005;29:149–153.
- 74 DeSesouza NM, Reinsberg SA, Scurr ED, Brewster JM, Payne GS: Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. *Br J Radiol* 2007;80:90–95.
- 75 Padhani AR: Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. *J Magn Reson Imaging* 2002;16:407–422.
- 76 Engelbrecht MR, Huisman HJ, Laheij RJ: Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. *Radiology* 2003;229:248–254.
- 77 Padhani AR, Gapinski CJ, Macvicar DA: Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. *Clin Radiol* 2000;55:99–109.
- 78 Alonzi R, Padhani AR, Allen C: Dynamic contrast enhanced MRI in prostate cancer. *Eur J Radiol* 2007;63:335–350.
- 79 Yuen JS, Thng CH, Tan PH, Khin LW, Phee SJ, Xiao D, Lau WK, Ng WS, Cheng CW: Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. *J Urol* 2004;171:1482–1486.
- 80 Ellis WJ, Brawer MK: Repeat prostate needle biopsy: who needs it? *J Urol* 1995;153:1496–1498.
- 81 Villers A, Puech P, Leroy X, et al: Dynamic contrast-enhanced MRI for preoperative identification of localised prostate cancer. *Eur Urol Suppl* 2007;6:525–532.
- 82 Kirkham AP, Emberton M, Allen C: How good is MRI at detecting and characterising cancer within the prostate? *Eur Urol* 2006;50:1163–1175.
- 83 Perrotti M, Han KR, Epstein RE, et al: Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: a pilot study. *J Urol* 1999;162:1314–1317.
- 84 Bhatia C, Phongkitkarun S, Booranapitaksonti D, Kochakarn W, Chaleumsanyakorn P: Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results. *J Med Assoc Thai* 2007;90:1391–1399.
- 85 Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Cattarino S, Lisi D, Gentilucci A, Alfarone A, Bernardo S, Passariello R, Gentile V: Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. *Clin Cancer Res* 2010;16:1875–1883.
- 86 Lawrentschuk N, Fleshner N: The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. *BJU Int* 2009;103:730–733.
- 87 Park BK, Lee HM, Kim CK, Choi HY, Park JW: Lesion localization in patients with previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen levels using diffusion-weighted imaging at three Tesla before rebiopsy. *Invest Radiol* 2008;43:789–793.